Other Clinical Trial - Association of FGF-23 & Parathyroid Hormone (PTH)

Status Completed

Clinical Trial Summary

The purpose of this study is to determine how levels of this newly-discovered hormone, called FGF-23, changes in the blood in response to a high calcium dialysis bath during a hemodialysis (HD) treatment, and how this relates to changes in the calcium and PTH levels. We are also studying the effects of dialysis and inflammation on the levels of Fetuin A.

We intend to prospectively study a cohort of end stage renal disease (ESRD) patients on hemodialysis in order to determine whether FDF-23 levels independently affect non-suppressible PTH levels. The relationship between Fetuin A and inflammatory markers will also be determined. By dialyzing patients on 3.5 mEq/L calcium dialysate bath, we seek any relationship between ionized calcium, FGF-23 and PTH.

Clinical Trial Description

The goal of this study is to ascertain whether there is a regulatory relationship between the novel phosphorus-regulating polypeptide fibroblast growth factor-23 (FGF-23), ionized calcium (iCa), and parathyroid hormone (PTH) levels. In addition, we will determine if there is an inverse relationship between Fetuin A levels and inflammatory markers, interleukin 6 (IL-6) and C-reactive protein (CRP), during a hemodialysis treatment.

All patients participating in this study will be off Zemplar and/or Sensipar for a washout period of approximately 4 weeks as these medications will interfere with the study. Patients will go through one designated research hemodialysis time for a blood draw. Blood draws will be taken during 4 separate intervals at 0, 45, 90 and 150 minutes. At each interval, 4 tubes of blood will be drawn.

There are no further required blood draws once each designated research HD session has been completed. At the conclusion of the designated research HD session, vitamin D analogue (Zemplar®) and/or Cinacalcet (Sensipar®) will be restarted, and the dose will be adjusted to reflect the subject's recent biochemical markers (Ca, Phos, and iPTH). ;

Study Design

Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00477516
Study type	Interventional
Source	University of Kansas Medical Center
Contact
Status	Completed
Phase	N/A
Start date	January 2007
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04087213` - Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD	N/A
Completed	`NCT02207088` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease	Phase 3
Not yet recruiting	`NCT03090828` - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease	N/A
Completed	`NCT02237521` - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease	N/A
Withdrawn	`NCT01691196` - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed	`NCT01394341` - Liraglutide Treatment to Patients With Severe Renal Insufficiency	Phase 4
Active, not recruiting	`NCT00247507` - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients	Phase 4
Completed	`NCT00307463` - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation	Phase 4
Recruiting	`NCT00155363` - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis	Phase 4
Completed	`NCT00234156` - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers	N/A
Completed	`NCT00586131` - Arterial pH and Total Body Nitrogen Balances in APD	Phase 4
Active, not recruiting	`NCT05027074` - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)	Phase 2
Recruiting	`NCT04575077` - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation	`NCT05001009` - Goals of Care Conversations Study	N/A
Completed	`NCT01756508` - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury	Phase 2
Recruiting	`NCT03862859` - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis	Phase 4
Terminated	`NCT03661229` - Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device	N/A
Completed	`NCT03288922` - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF	N/A
Completed	`NCT02360748` - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients	N/A
Completed	`NCT02572882` - Gut Microbiome and p-Inulin in Hemodialysis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms